Organon Competitors
| OGN Stock | USD 7.39 0.33 4.67% |
Organon vs Alvotech Correlation
Good diversification
The correlation between Organon Co and ALVO is -0.03 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Organon Co and ALVO in the same portfolio, assuming nothing else is changed.
Moving against Organon Stock
| 0.37 | 21P | Aurora Cannabis | PairCorr |
| 0.32 | WEED | Canopy Growth Corp | PairCorr |
| 0.31 | KG | Kestrel Group Symbol Change | PairCorr |
Organon Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Organon and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Organon and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Organon does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Organon Stock performing well and Organon Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Organon's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PAHC | 2.16 | 0.22 | 0.08 | 0.42 | 2.39 | 4.15 | 24.25 | |||
| AUPH | 1.41 | (0.09) | 0.00 | (0.13) | 0.00 | 3.57 | 11.59 | |||
| NUVB | 3.90 | 0.49 | 0.10 | 0.51 | 4.41 | 7.33 | 68.61 | |||
| AVDL | 0.79 | 0.28 | 0.14 | (0.49) | 0.84 | 0.70 | 29.13 | |||
| TLRY | 4.86 | (0.58) | 0.00 | (1.05) | 0.00 | 7.64 | 54.17 | |||
| HRMY | 1.46 | 0.14 | 0.07 | 0.23 | 1.75 | 3.38 | 10.69 | |||
| MD | 1.44 | (0.06) | 0.00 | (0.74) | 0.00 | 2.95 | 7.73 | |||
| GRDN | 2.05 | 0.12 | 0.06 | 0.14 | 2.47 | 4.77 | 13.96 | |||
| SEM | 1.17 | 0.26 | 0.24 | 0.29 | 0.80 | 2.25 | 13.50 | |||
| ALVO | 2.65 | (0.26) | 0.00 | (0.20) | 0.00 | 6.42 | 16.71 |
Cross Equities Net Income Analysis
Compare Organon and related stocks such as Phibro Animal Health, Aurinia Pharmaceuticals, and Nuvation Bio Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAHC | 10.1 M | 7 M | 24.9 M | (3.1 M) | 60.3 M | 82.7 M | 64.6 M | 64.9 M | 54.7 M | 33.6 M | 54.4 M | 49.2 M | 32.6 M | 2.4 M | 48.3 M | 55.5 M | 58.3 M |
| AUPH | (2.2 M) | (2.4 M) | (9.7 M) | (2.5 M) | (16.6 M) | (18.6 M) | (23.3 M) | (70.8 M) | (64.1 M) | (88.4 M) | (102.7 M) | (181 M) | (108.2 M) | (78 M) | 5.8 M | 5.2 M | 5.4 M |
| NUVB | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (33.6 M) | (41.7 M) | (86.8 M) | (104.2 M) | (75.8 M) | (567.9 M) | (511.1 M) | (485.6 M) |
| AVDL | (6.9 M) | (8.8 M) | (3.2 M) | (42.9 M) | (84.9 M) | 40.7 M | (41.3 M) | 67.3 M | (95.3 M) | (33.2 M) | 7 M | (77.3 M) | (137.5 M) | (160.3 M) | (48.8 M) | (43.9 M) | (41.8 M) |
| TLRY | (96.4 K) | (96.4 K) | (42 K) | (42 K) | (5.3 M) | 305.1 K | 3.1 M | 22.8 M | (25 M) | (102.5 M) | (443.7 M) | (601 M) | (2 B) | (333.8 M) | (3 B) | (2.7 B) | (2.6 B) |
| HRMY | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (152 M) | (36.9 M) | 34.6 M | 181.5 M | 128.9 M | 145.5 M | 167.3 M | 175.7 M |
| MD | 5.4 M | 218 M | 240.9 M | 280.5 M | 317.3 M | 336.3 M | 324.9 M | 320.4 M | 268.6 M | (1.5 B) | (796.5 M) | 131 M | 66.3 M | (60.4 M) | (99.1 M) | (89.2 M) | (84.7 M) |
| GRDN | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 21.7 M | 19.9 M | 16.3 M | 35.4 M | 23.9 M | (87.3 M) | (78.6 M) | (74.6 M) |
| SEM | (27.9 M) | 107.8 M | 148.2 M | 114.4 M | 120.6 M | 130.7 M | 115.4 M | 177.2 M | 137.8 M | 148.4 M | 259 M | 402.2 M | 159 M | 243.5 M | 214 M | 246.1 M | 151.6 M |
| ALVO | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (170 M) | (101.5 M) | (513.6 M) | (551.7 M) | (231.9 M) | (208.7 M) | (219.1 M) |
Organon and related stocks such as Phibro Animal Health, Aurinia Pharmaceuticals, and Nuvation Bio Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Organon financial statement analysis. It represents the amount of money remaining after all of Organon Co operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Organon Competitive Analysis
The better you understand Organon competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Organon's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Organon's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Organon Competition Performance Charts
Five steps to successful analysis of Organon Competition
Organon's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Organon in relation to its competition. Organon's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Organon in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Organon's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Organon, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Organon position
In addition to having Organon in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alternative Energy Thematic Idea Now
Alternative Energy
Large and mid-size companies, ETFs and funds that are either investing or directly involved in providing energy derived from sources not connected to fossil fuels, do not consume natural resources, and do not harm the environment. This includes wind power, nuclear and solar energy, biofuel, ethanol, hydrogen and others alternative sources of energy. The Alternative Energy theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Energy Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Organon Correlation with its peers. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Will Pharmaceuticals sector continue expanding? Could Organon diversify its offerings? Factors like these will boost the valuation of Organon. Anticipated expansion of Organon directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Organon data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.56) | Earnings Share 1.91 | Revenue Per Share | Quarterly Revenue Growth (0.05) | Return On Assets |
Investors evaluate Organon using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Organon's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Organon's market price to deviate significantly from intrinsic value.
It's important to distinguish between Organon's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Organon should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Organon's market price signifies the transaction level at which participants voluntarily complete trades.